Patents by Inventor Gregory William Endres

Gregory William Endres has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11884624
    Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: January 30, 2024
    Assignee: CAYMAN CHEMICAL COMPANY, INC.
    Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
  • Publication number: 20230050318
    Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
    Type: Application
    Filed: June 9, 2021
    Publication date: February 16, 2023
    Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
  • Patent number: 11066361
    Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: July 20, 2021
    Assignee: CAYMAN CHEMICAL COMPANY, INC.
    Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
  • Publication number: 20210003488
    Abstract: The present disclosure provides a set of spiked matrix standards comprising: one or more carriers, each carrier comprising: (a) a reference standard analyte in an amount that is different in each carrier; and (b) a blank matrix that is in admixture or in contact with the reference standard analyte. Methods for preparing and quantitating an analyte in a test sample comprises (a) providing one or more test samples to be tested for the presence of the analyte (b) providing a set of spiked matrix standards; (c) processing the standards and test samples and (d) quantitating the amount of analyte in each of the standards and test samples.
    Type: Application
    Filed: July 2, 2020
    Publication date: January 7, 2021
    Applicant: PinPoint Testing, LLC
    Inventors: Gregory William ENDRES, Jeffery H. MORAN
  • Patent number: 10729810
    Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: August 4, 2020
    Assignees: CAYMAN CHEMICAL COMPANY, INC, MYOMETRICS LLC
    Inventors: Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Gregory William Endres, Fred Lawrence Ciske, Thomas Allen Owen, James Paul O'Malley
  • Publication number: 20200207709
    Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 2, 2020
    Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
  • Patent number: 10556862
    Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 11, 2020
    Assignee: CAYMAN CHEMICAL COMPANY, INC.
    Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Komilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
  • Publication number: 20200002261
    Abstract: The present invention provides processes for preparing a prostacyclin analogue of Formula I or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.
    Type: Application
    Filed: September 11, 2019
    Publication date: January 2, 2020
    Applicant: CAYMAN CHEMICAL COMPANY INCORPORATED
    Inventors: Kirk William Hering, Gilles CHAMBOURNIER, Gregory William ENDRES, Victor FEDIJ, Thomas James KRELL, II, Hussien Mahmoud MAHMOUD
  • Patent number: 10450257
    Abstract: The present invention provides processes for preparing a prostacyclin analog of Formula I or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: October 22, 2019
    Assignee: Cayman Chemical Company Incorporated
    Inventors: Kirk William Hering, Gilles Chambournier, Gregory William Endres, Victor Fedij, Thomas James Krell, II, Hussein Mahmoud Mahmoud
  • Publication number: 20190092722
    Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
    Type: Application
    Filed: October 9, 2018
    Publication date: March 28, 2019
    Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Komilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
  • Patent number: 10155716
    Abstract: The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: December 18, 2018
    Assignee: Cayman Chemical Company Incorporated
    Inventors: Gilles Chambournier, Gregory William Endres, Kirk William Hering, Victor Fedij, Hussein Mahmoud Mahmoud
  • Publication number: 20180141889
    Abstract: The present invention provides processes for preparing a prostacyclin analogue of Formula I or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.
    Type: Application
    Filed: January 18, 2018
    Publication date: May 24, 2018
    Applicant: CAYMAN CHEMICAL COMPANY INCORPORATED
    Inventors: Kirk William Hering, Gilles Chambournier, Gregory William Endres, Victor Fedij, Thomas James Krell, II, Hussein Mahmoud Mahmoud
  • Publication number: 20180118656
    Abstract: The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Applicant: Cayman Chemical Company Incorporated
    Inventors: Gilles Chambournier, Gregory William Endres, Kirk William Hering, Victor Fedij, Hussein Mahmoud Mahmoud
  • Patent number: 9908834
    Abstract: The present invention provides processes for preparing a prostacyclin analog of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 6, 2018
    Assignee: Cayman Chemical Company Incorporated
    Inventors: Kirk William Hering, Gilles Chambournier, Gregory William Endres, Victor Fedij, Thomas James Krell, II, Hussein Mahmoud Mahmoud
  • Patent number: 9890104
    Abstract: The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: February 13, 2018
    Assignee: Cayman Chemical Company Incorporated
    Inventors: Gilles Chambournier, Gregory William Endres, Kirk William Hering, Victor Fedij, Hussein Mahmoud Mahmoud
  • Publication number: 20170297995
    Abstract: The present invention provides processes for preparing a prostacyclin analogue of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.
    Type: Application
    Filed: May 1, 2017
    Publication date: October 19, 2017
    Applicant: CAYMAM CHEMICAL COMPANY INCORPORATED
    Inventors: Kirk William Hering, Gilles Chambournier, Gregory William Endres, Victor Fedij, Thomas James Krell, II, Hussein Mahmoud Mahmoud
  • Patent number: 9701630
    Abstract: Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: July 11, 2017
    Assignees: Cayman Chemical Company, Inc., Myometrics, LLC
    Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Thomas Allen Owen, James Paul O'Malley
  • Patent number: 9688627
    Abstract: Disclosed herein are compounds of formula (I) wherein L1, L2, L3, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 27, 2017
    Assignee: CAYMAN CHEMICAL COMPANY, INC.
    Inventors: Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Gregory William Endres, Andriy Komilov, James Bernard Kramer, Adam Uzieblo, Fred Lawrence Ciske, Kirk M. Maxey, James Paul O'Malley, Thomas Allen Owen
  • Patent number: 9676712
    Abstract: Disclosed herein are compounds of formula (I) wherein L1, L2, L3, R1, R4, R5, and R6 are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 13, 2017
    Assignee: CAYMAN CHEMICAL COMPANY, INC.
    Inventors: Stephen Douglas Barrett, Bradlee David Germain, Adam Uzieblo, Fred Lawrence Ciske, Gregory William Endres, Andriy Kornilov, Kirk M. Maxey, James Paul O'Malley, Thomas Allen Owen
  • Publication number: 20170066751
    Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
    Type: Application
    Filed: September 16, 2016
    Publication date: March 9, 2017
    Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Komilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey